Atossa Therapeutics (NASDAQ:ATOS) issued its earnings results on Wednesday. The company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01, MarketWatch Earnings reports.
Shares of Atossa Therapeutics stock opened at $1.53 on Friday. The firm has a 50-day moving average of $1.87 and a 200-day moving average of $2.71. The stock has a market cap of $16.05 million, a PE ratio of -1.13 and a beta of 2.59. Atossa Therapeutics has a 52-week low of $0.76 and a 52-week high of $5.08.
ATOS has been the topic of several research reports. Maxim Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Atossa Therapeutics in a report on Friday, September 18th. Ascendiant Capital Markets started coverage on shares of Atossa Therapeutics in a research report on Thursday, September 17th. They issued a “buy” rating and a $7.00 target price for the company.
Atossa Therapeutics, Inc develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, conducting two Phase II studies, which is an active metabolite of tamoxifen to treat and prevent breast cancer.
Further Reading: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.